TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10655964

Group type: EXPERIMENTAL
Intervention: Retinyl palmitate by inhalation (2 puffs of aerosol containing 1 mg per delivery, total 2 mg over 3 months)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo aerosol without retinyl palmitate
Number of subjects: 25
Study: 8910235

Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Acetylcholine vehicle
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sodium nitroprusside (SNP) vehicle
Number of subjects: 8
Study: 1715478

Group type: EXPERIMENTAL
Intervention: nitrendipine 10 mg b.i.d. (n = 39)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: nitrendipine 20 mg o.d. (n = 39)
Number of subjects: 78

Group type: COMPARATOR
Intervention: nitrendipine 10 mg b.i.d. (n = 32)
Number of subjects: 78

Group type: COMPARATOR
Intervention: nitrendipine 20 mg o.d. (n = 28)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: nitrendipine 20 mg o.d.
Number of subjects: 78

Group type: COMPARATOR
Intervention: nitrendipine 10 mg b.i.d.
Number of subjects: 78
Study: 6358177

Group type: EXPERIMENTAL
Intervention: Thienamycin formamidine/renal dipeptidase inhibitor
Number of subjects: 21

Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 21
Study: 30268384

Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ischemia-reperfusion without intervention
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: iv administration of GLP-1 receptor antagonist exendin(9-39) + ischemia-reperfusion + RIC
Number of subjects: 12
Study: 29073347

Group type: EXPERIMENTAL
Intervention: Atacicept 75 mg
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Atacicept 150 mg
Number of subjects: 306

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study: 26797875

Group type: EXPERIMENTAL
Intervention: Novel disposable suture device
Number of subjects: 582

Group type: COMPARATOR
Intervention: Conventional suture approach
Number of subjects: 582
Study: 24599566

Group type: EXPERIMENTAL
Intervention: epinephrine plus 1% lidocaine hydrochloride (group B)
Number of subjects: 42

Group type: COMPARATOR
Intervention: epinephrine only (group A)
Number of subjects: 42
Study: 22160637

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, epirubicin, and fluorouracil (CEF)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, and fluorouracil (CMF)
Number of subjects: 403
Study: 19672937

Group type: EXPERIMENTAL
Intervention: Surgery-related mortality
Number of subjects: 15614

Group type: EXPERIMENTAL
Intervention: Total morbidity
Number of subjects: 15614

Group type: EXPERIMENTAL
Intervention: Bile leakage
Number of subjects: 15614

Group type: EXPERIMENTAL
Intervention: Postresectional liver failure
Number of subjects: 15614

Group type: COMPARATOR
Intervention: Operative mortality
Number of subjects: 15614
Study: 17426331

Group type: EXPERIMENTAL
Intervention: HAES group
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: SS group
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 144
Study: 15781339

Group type: COMPARATOR
Intervention: HSCT recipients
Number of subjects: 139
Study: 12148881

Group type: EXPERIMENTAL
Intervention: Prophylactic doses of nadroparin (Fraxiparine)
Number of subjects: 46

Group type: COMPARATOR
Intervention: No heparin prophylaxis (Control)
Number of subjects: 46
Study: 10589004

Group type: EXPERIMENTAL
Intervention: HFA-BDP 100 microg/d
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: HFA-BDP 400 microg/d
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: HFA-BDP 800 microg/d
Number of subjects: 323

Group type: COMPARATOR
Intervention: CFC-BDP 100 microg/d
Number of subjects: 323

Group type: COMPARATOR
Intervention: CFC-BDP 400 microg/d
Number of subjects: 323

Group type: COMPARATOR
Intervention: CFC-BDP 800 microg/d
Number of subjects: 323
Study: 8934250

Group type: EXPERIMENTAL
Intervention: Nafarelin (NAF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Leuprolide acetate (LA)
Number of subjects: 0
Study: 1855751

Group type: EXPERIMENTAL
Intervention: Phytodolor N (3 x 30 drops daily for 3 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 6338683

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 31615057

Group type: EXPERIMENTAL
Intervention: Typical Korean Diet (TKD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recommended American Diet (RAD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Typical American Diet (TAD)
Number of subjects: 0
Study: 29684979

Group type: EXPERIMENTAL
Intervention: Supported exercise at 80° arm elevation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Supported exercise at 120° arm elevation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Unsupported exercise at 80° arm elevation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Unsupported exercise at 120° arm elevation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 120° arm elevation (both unsupported and supported)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 80° arm elevation (both unsupported and supported)
Number of subjects: 12
Study: 27981528

Group type: EXPERIMENTAL
Intervention: 0.1 g Bayaspirin (ASA II group) administered at draught before sleep
Number of subjects: 150

Group type: COMPARATOR
Intervention: 30 mg Adalat (control group) administered orally once a day
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 0.1 g Bayaspirin (ASA I group) administered at draught in the morning
Number of subjects: 150
Study: 24571870

Group type: EXPERIMENTAL
Intervention: 20 ml of 0.5% ropivacaine injected peri‐incisionally with pulmonary recruitment manoeuvre (Group 2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 20 ml of 0.5% ropivacaine injected peri‐incisionally without pulmonary recruitment manoeuvre (Group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group 2 (ropivacaine with pulmonary recruitment manoeuvre)
Number of subjects: 60
Study: 23259913

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (daily sessions)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (for compliant women)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (non-compliant women)
Number of subjects: 89
Study: 20139780

Group type: COMPARATOR
Intervention: Strength Training (ST)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Power Training (PT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study: 18412873

Group type: EXPERIMENTAL
Intervention: Two passes of microdermabrasion (MDA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Three passes of microdermabrasion (MDA)
Number of subjects: 10
Study: 16109056

Group type: EXPERIMENTAL
Intervention: Eletriptan 20 mg
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Eletriptan 40 mg
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: Eletriptan 40 mg (mild pain intensity)
Number of subjects: 613

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 613
Study: 11823892

Group type: EXPERIMENTAL
Intervention: Smoked cocaine (0, 6, 12, or 25 mg cocaine base, depending on the session) administered during the follicular phase.
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Smoked cocaine (0, 6, 12, or 25 mg cocaine base, depending on the session) administered during the luteal phase.
Number of subjects: 11
Study: 10459958

Group type: EXPERIMENTAL
Intervention: Zidovudine (300 mg tablets), one tablet twice daily until the onset of labour, one tablet at onset of labour, and one tablet every 3 h until delivery
Number of subjects: 280

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Zidovudine (300 mg tablets)
Number of subjects: 280
Study: 7617467

Group type: EXPERIMENTAL
Intervention: 99mTc‐MAG3 (300 MBq)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 123I‐OIH (37 MBq)
Number of subjects: 12
Study: 2240110

Group type: EXPERIMENTAL
Intervention: Erythromycin treatment
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study: 576887

Group type: EXPERIMENTAL
Intervention: 1,500 mg/day of diethylstibestrol (DES)
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: 150 mg/day of diethylstibestrol (DES)
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: 15 mg/day of diethylstibestrol (DES)
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: 1.5 mg/day of diethylstibestrol (DES)
Number of subjects: 523
Study: 31277784

Group type: EXPERIMENTAL
Intervention: Standard care and educational seminar
Number of subjects: 255
Study: 28333536

Group type: EXPERIMENTAL
Intervention: Mom-Net intervention (8-session, Internet-facilitated cognitive-behavioral treatment)
Number of subjects: 266

Group type: COMPARATOR
Intervention: Motivational Interviewing and Referral to Services (MIRS)
Number of subjects: 266
Study: 25807815

Group type: COMPARATOR
Intervention: TVT-O alone
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: TVT-O with biofeedback pelvic floor electrical stimulation
Number of subjects: 120
Study: 23160726

Group type: EXPERIMENTAL
Intervention: Imeglimin (1,500 mg twice a day)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Placebo added to metformin (1,500-2,000 mg/day)
Number of subjects: 156
Study: 21777737

Group type: EXPERIMENTAL
Intervention: Topical treatment with CERTIFECT (fipronil, amitraz, and (S)-methoprene) applied 28 days prior to tick infestation
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Topical treatment with CERTIFECT applied 21 days prior to tick infestation
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Topical treatment with CERTIFECT applied 14 days prior to tick infestation
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Topical treatment with CERTIFECT applied 7 days prior to tick infestation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Untreated control group (7 dogs)
Number of subjects: 28
Study: 20635778

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for psychosis, focusing on education about symptoms and cognitive models, including collaborative exploration of thoughts and schemas surrounding delusions and hallucinations.
Number of subjects: 0
Study: 17083392

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.2 mg)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Doxazosin (2 mg)
Number of subjects: 101
Study: 15070001

Group type: EXPERIMENTAL
Intervention: Assessment of motor and somatosensory function
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Conventional structured interview questions addressing awareness of various capacities
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Pre- and post-performance estimates of ability on tasks
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Estimates of current ability on bilateral and unilateral tasks
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Explanations of bimanual task performance
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Double dissociation analysis
Number of subjects: 64
Study: 11768548

Group type: EXPERIMENTAL
Intervention: Alcohol (pharmacology plus expectancy)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Placebo (expectancy only)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (no pharmacology and no expectancy)
Number of subjects: 48
Study: 9271767

Group type: EXPERIMENTAL
Intervention: Circuit weight training (CWT) at 40 to 60% of maximum voluntary contraction (n = 12)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (n = 14)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Circuit weight training (CWT)
Number of subjects: 26
Study: 8140874

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia with propofol
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Propofol for induction followed by isoflurane anaesthesia
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Thiopental for induction followed by isoflurane anaesthesia
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Overall (all groups combined)
Number of subjects: 90
Study: 3048784

Group type: EXPERIMENTAL
Intervention: New immunoinhibition method for pancreatic isoamylase determination
Number of subjects: 0
Study: 30946207

Group type: EXPERIMENTAL
Intervention: Alirocumab (75 mg every 2 weeks; increased to 150 mg at Week 12 if LDL-C ≥ 70 mg/dL at Week 8)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 116

Group type: COMPARATOR
Intervention: Alirocumab and Placebo
Number of subjects: 116
Study: 28257919

Group type: EXPERIMENTAL
Intervention: MoodSwings 2.0 online intervention for bipolar disorder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 0
Study: 27651331

Group type: EXPERIMENTAL
Intervention: Exenatide plus dapagliflozin
Number of subjects: 695

Group type: COMPARATOR
Intervention: Exenatide alone
Number of subjects: 695

Group type: COMPARATOR
Intervention: Dapagliflozin alone
Number of subjects: 695
Study: 23330822

Group type: EXPERIMENTAL
Intervention: 0.5% tetracaine + naphazoline
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: 5% lidocaine
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: topical diclofenac + tobramycin
Number of subjects: 156

Group type: COMPARATOR
Intervention: topical tobramycin
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: topical naphazoline
Number of subjects: 156
Study: 21105974

Group type: EXPERIMENTAL
Intervention: 5% natamycin (group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 1% voriconazole (group B)
Number of subjects: 30
Study: 19050973

Group type: EXPERIMENTAL
Intervention: Sentinel-lymph-node biopsy followed by axillary clearance if sentinel node positive or not detected (SNBM)
Number of subjects: 1088

Group type: COMPARATOR
Intervention: Routine axillary clearance (RAC)
Number of subjects: 1088

Group type: COMPARATOR
Intervention: Sentinel-lymph-node biopsy (SNB)
Number of subjects: 1088
Study: 16908618

Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic surgery
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional thoracostomy drainage
Number of subjects: 18
Study: 15017615

Group type: EXPERIMENTAL
Intervention: Lumiracoxib (800 mg every day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Naproxen (500 mg twice a day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 11349930

Group type: EXPERIMENTAL
Intervention: Rigid gas-permeable contact lenses
Number of subjects: 116
Study: 9230275

Group type: EXPERIMENTAL
Intervention: Daily supplementation of 0.7 mg free folic acid in cereal for 2 months followed by 2.0 mg free folic acid via a tablet for 4 months
Number of subjects: 64

Group type: COMPARATOR
Intervention: Normal levels of folate, vitamin B12, and homocysteine
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Normal folate and vitamin B12, but homocysteine levels >10 micromol/l
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Men with one or more abnormal blood values for folate, vitamin B12 or homocysteine
Number of subjects: 64
Study: 8197064

Group type: EXPERIMENTAL
Intervention: Intensive therapy program for behaviorally disordered mentally handicapped patients
Number of subjects: 0
Study: 3372923

Group type: EXPERIMENTAL
Intervention: Applied kinesiology assessment of nutrient status
Number of subjects: 11

Group type: COMPARATOR
Intervention: Applied kinesiology assessment compared to standard laboratory tests
Number of subjects: 11

Group type: COMPARATOR
Intervention: Applied kinesiology assessment compared to computerized isometric muscle testing
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nutrient supplementation (thiamin, zinc, vitamin A, ascorbic acid)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (pectin and sucrose)
Number of subjects: 11
Study: 29433545

Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation treatment using the GRADIOR programme
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Psychosocial stimulation intervention (PSS) using the ehcoBUTLER platform
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Combined treatment consisting of GRADIOR and ehcoBUTLER
Number of subjects: 400

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 400
Study: 27756783

Group type: EXPERIMENTAL
Intervention: Addition of 7 lipid species to a base model (14 traditional risk factors and medications)
Number of subjects: 3779

Group type: EXPERIMENTAL
Intervention: Incorporation of 4 lipid species into the base model
Number of subjects: 3779
Study: 24831037

Group type: EXPERIMENTAL
Intervention: Automated telecommunication-based reminders (daily messages via text or voice)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 70
Study: 22935508

Group type: EXPERIMENTAL
Intervention: Immunosuppressive treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral ulcers
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 10 or more oral ulcers during 6 months
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Genital ulcers, follicular lesions, and erythema nodosum
Number of subjects: 30
Study: 19243993

Group type: EXPERIMENTAL
Intervention: Group 1 (G1) - Large to small muscle group exercises
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group 2 (G2) - Small to large muscle group exercises
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group (CG) - No exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Small muscle group exercises (comparison between G1 and G2)
Number of subjects: 0
Study: 18174609

Group type: EXPERIMENTAL
Intervention: High-dose regimen (HD): two cycles of E(90)C(600) every 2 weeks followed by two cycles of E(90)C(3000)Thiotepa(400) every 3 weeks.
Number of subjects: 236

Group type: COMPARATOR
Intervention: Dose-dense conventional chemotherapy (DD): four cycles of E(90)C(600) followed by three cycles of C(600)M(40)F(600) every 2 weeks.
Number of subjects: 236
Study: 16900444

Group type: EXPERIMENTAL
Intervention: Falls data collection over a 12-month period
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Falls occurring outside the home during leisure activities
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Gender influence on fall characteristics
Number of subjects: 293
Study: 12565982

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Modified Radical Mastectomy (MRM)
Number of subjects: 164
Study: 11103234

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemoimmunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study: 8839500

Group type: EXPERIMENTAL
Intervention: Standard diet with 10 mg total carotenoids/d for two cycles
Number of subjects: 12
Study: 8098281

Group type: EXPERIMENTAL
Intervention: Ibopamine (3 x 100 mg/day p.o.)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 2441736

Group type: EXPERIMENTAL
Intervention: PVB chemotherapy (cisplatin, vinblastine, and bleomycin)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 47
Study: 31345049

Group type: EXPERIMENTAL
Intervention: Breastfeeding training during prenatal and postnatal periods
Number of subjects: 120
Study: 29940166

Group type: EXPERIMENTAL
Intervention: rAAV2.REP1 (0.1 mL containing 10^11 genome particles)
Number of subjects: 6
Study: 27777234

Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Coronary Angiography
Number of subjects: 340
Study: 25455617

Group type: EXPERIMENTAL
Intervention: Oscillating-rotating power brush with a novel brush head
Number of subjects: 94

Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 94
Study: 23756247

Group type: EXPERIMENTAL
Intervention: Supraclavicular approach (SC)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Infraclavicular approach (IC)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 98
Study: 21702233

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (loading dose 1 g over 10 min then infusion of 1 g over 8 h)
Number of subjects: 20211

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20211
Study: 18988471

Group type: EXPERIMENTAL
Intervention: Injector
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Forceps
Number of subjects: 46

Group type: COMPARATOR
Intervention: Both techniques
Number of subjects: 46
Study: 15730542

Group type: COMPARATOR
Intervention: DVP delayed-release/sprinkle
Number of subjects: 31

Group type: COMPARATOR
Intervention: DVP sprinkle formulation
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: DVP extended-release tablets
Number of subjects: 31
Study: 12538173

Group type: EXPERIMENTAL
Intervention: Allon thermoregulation (AT), n = 30
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine thermal care (RTC), n = 30
Number of subjects: 60
Study: 11085961

Group type: EXPERIMENTAL
Intervention: Trained (TR) group underwent a residential exercise program at 85% of maximum heart rate, consisting of 2 daily sessions 6 times a week for 2 weeks.
Number of subjects: 97

Group type: COMPARATOR
Intervention: Untrained (UTR) group, control group, no intervention.
Number of subjects: 97
Study: 8784318

Group type: EXPERIMENTAL
Intervention: Roux-en-Y esophagojejunostomy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Hunt-Rodino-Lawrence pouch (HRL)
Number of subjects: 27
Study: 1623657

Group type: EXPERIMENTAL
Intervention: diltiazem CD (n = 61)
Number of subjects: 127

Group type: COMPARATOR
Intervention: placebo (n = 66)
Number of subjects: 127
Study: 3926322

Group type: EXPERIMENTAL
Intervention: Naproxen sodium (275 mg each, 3 tablets)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Ergotamine combination (2 mg ergotamine tartrate, 91.5 mg caffeine, 50 mg cyclizine chlorhydrate, 1 tablet)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Naproxen sodium
Number of subjects: 114

Group type: COMPARATOR
Intervention: Ergotamine combination
Number of subjects: 114
Study: 31079072

Group type: EXPERIMENTAL
Intervention: Metformin (n=45)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (n=45)
Number of subjects: 90
Study: 29859789

Group type: EXPERIMENTAL
Intervention: Hypofractionated whole-breast radiation therapy (RT)
Number of subjects: 348